207801-52-3

Usage

Uses

Used in Pharmaceutical Industry:
N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide is used as a chemical intermediate for the synthesis of various drugs and bioactive compounds. Its unique structure allows for the development of new pharmaceuticals with potential therapeutic applications.
Used in Antimicrobial Agents:
In the field of antimicrobials, N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide is used as a starting material for creating new agents. The sulfonamide group in its structure is known to contribute to antimicrobial properties, making it a promising candidate for the development of treatments against resistant infections.
Used in Antineoplastic Agents:
N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide is also utilized as a component in the design of antineoplastic agents. Its structure may be harnessed to develop compounds that combat cancer by interfering with the growth and spread of tumor cells.
Used in Synthetic Chemistry:
In synthetic chemistry, N-(5-bromopyridin-2-yl)-4-methylbenzenesulfonamide is used as a building block for the preparation of heterocyclic compounds with biological activity. Its bromopyridine moiety is particularly useful for creating novel compounds with potential applications in various chemical and biological fields.

Upstream product

• 1072-97-5 5-bromo-2-pyridylamine 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1005785-49-8 2-[5-bromo-2-{[(4-methylphenyl)sulfonyl]imino}pyridin-1(2H)-yl]acetamide 
• 937014-94-3 (Z)-2-(5-bromo-2-(tosylimino)pyridin-1(2H)-yl)acetamide 
• 947249-08-3 N-(6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)imidazo[1,2-a]pyridine-2-yl)acetamide 
• 1162680-84-3 N-(6-bromoimidazo[1,2-a]pyridin-2-yl)acetamide 
• 947248-52-4 6-bromoimidazole[1,2-a]pyridine-2-amine 
• 504413-35-8 N-(6-bromoimidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide 
• 1192831-91-6 N-(6-{3-[(ethylamino)sulfonyl]phenyl}imidazo[1,2-a]pyridin-2-yl)-2,2,2-trifluoroacetamide 
• 1192832-26-0 2,2,2-trifluoro-N-{6-[3-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-2-yl}acetamide 
• 1192831-93-8 N-{6-[3-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-2-yl}acetamide 
• 1192832-27-1 6-[3-(methylsulfonyl)phenyl]imidazo[1,2-a]pyridin-2-amine 

Relevant academic research and scientific papers

HETEROARYL COMPOUNDS AS NECROSIS INHIBITORS, COMPOSITION AND METHOD USING THE SAME

The present disclosure provides heteroaryl compounds of Formula (I), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosis. Formula (I) i

HETEROARYL COMPOUNDS AS INHIBITORS OF NECROSIS, COMPOSITION AND APPLICATION THEREOF

The present disclosure provides heteroaryl compounds of formulas (I), (Ia) and (Ib), processes for their preparation, pharmaceutical compositions containing them, and their use in the treatment of diseases and disorders, arising from or related to necrosi

FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE

The invention relates to compounds of formula (I) for the regulation of phosphoinositides 3-kinases activity and related diseases.

FUSED BICYCLIC COMPOUNDS AND USE THEREOF AS PI3K INHIBITORS

The invention relates to compounds of formula (I), for the regulation of phosphoinositides 3-kinases activity and related diseases.

Inhibitors of PI3 kinase

The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt thereof, that inhibit phosphoinositide 3-kinase; methods of treating diseases or conditions, such as cancer, using the compounds; and pharmaceutical compositions containing the compounds.

BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS

Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

PI-3 KINASE INHIBITORS AND METHODS OF THEIR USE

Phosphatidylinositol (PI) 3 kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceuticall

Synthesis of Functionalized 3-Pyridyl Methyl Ketones

A synthesis of 3-pyridyl methyl ketones is described that employs a palladium-catalyzed olefination of 3-bromopyridines with butyl vinyl ether followed by acid hydrolysis of the intermediate pyridyl vinyl ether in situ. This method has been applied to bromoquinoline substrates as well. The reaction is compatible with a variety of functional groups.